{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:58:42Z","timestamp":1770645522412,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01632-9","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T09:32:39Z","timestamp":1748079159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of olanzapine as an antiemetic drug for transcatheter arterial chemoembolization for hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Kyoko","family":"Oura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tadokoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shima","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sanomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Himoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1632_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1632_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 7, 6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1632_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68, 723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913 (2018).","journal-title":"Hepatology"},{"key":"1632_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 11, 317\u2013370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9 (2017).","journal-title":"Hepatol. Int."},{"key":"1632_CR5","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. Electronic address, E. E. E. & European association for the study of the, L. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019 (2018).","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"1632_CR6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2214\/AJR.21.26806","volume":"218","author":"AA Rmilah","year":"2022","unstructured":"Rmilah, A. A. et al. Association of cirrhosis and other patient and procedural characteristics with postembolization syndrome after bland hepatic artery embolization for hepatic malignancy. AJR Am. J. Roentgenol. 218, 1030\u20131039. https:\/\/doi.org\/10.2214\/AJR.21.26806 (2022).","journal-title":"AJR Am. J. Roentgenol."},{"key":"1632_CR7","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2022.0395","author":"HN Lee","year":"2023","unstructured":"Lee, H. N. & Hyun, D. Complications related to transarterial treatment of hepatocellular carcinoma: A comprehensive review. Korean J. Radiol. https:\/\/doi.org\/10.3348\/kjr.2022.0395 (2023).","journal-title":"Korean J. Radiol."},{"key":"1632_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh, P. J. et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy.J. Clin. Oncol. 15, 103\u2013109. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.103 (1997).","journal-title":"J. Clin. Oncol."},{"key":"1632_CR9","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro, M. et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. 25, 1328\u20131333. https:\/\/doi.org\/10.1093\/annonc\/mdu101 (2014).","journal-title":"Ann. Oncol."},{"key":"1632_CR10","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1002\/cncr.28892","volume":"120","author":"DL Barton","year":"2014","unstructured":"Barton, D. L. et al. Phase III double-blind, placebo-controlled study of Gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120, 3575\u20133583. https:\/\/doi.org\/10.1002\/cncr.28892 (2014).","journal-title":"Cancer"},{"key":"1632_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster, F. P. et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87\u201396. https:\/\/doi.org\/10.1016\/0893-133X(94)00129-N (1996).","journal-title":"Neuropsychopharmacology"},{"key":"1632_CR12","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh, P. J. et al. Antiemetics: ASCO guideline update. J. Clin. Oncol. 38, 2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1632_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"1632_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000439101","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo, M., Kitano, M., Sakurai, T. & Nishida, N. General rules for the clinical and pathological study of primary liver cancer, nationwide Follow-Up survey and clinical practice guidelines: The outstanding achievements of the liver cancer study group of Japan. Dig. Dis. 33, 765\u2013770. https:\/\/doi.org\/10.1159\/000439101 (2015).","journal-title":"Dig. Dis."},{"key":"1632_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R., Llovet, J. M. & Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30, 52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132 (2010).","journal-title":"Semin Liver Dis."},{"key":"1632_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari, R. M. et al. Olanzapine for the prevention of Chemotherapy-Induced nausea and vomiting. N Engl. J. Med. 375, 134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725 (2016).","journal-title":"N Engl. J. Med."},{"key":"1632_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto, H. et al. Olanzapine 5\u00a0mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3 (2020).","journal-title":"Lancet Oncol."},{"key":"1632_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0014-2999(01)01399-1","volume":"430","author":"FP Bymaster","year":"2001","unstructured":"Bymaster, F. P. et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur. J. Pharmacol. 430, 341\u2013349. https:\/\/doi.org\/10.1016\/s0014-2999(01)01399-1 (2001).","journal-title":"Eur. J. Pharmacol."},{"key":"1632_CR19","doi-asserted-by":"publisher","first-page":"e23191","DOI":"10.1097\/MD.0000000000023191","volume":"99","author":"L Chang","year":"2020","unstructured":"Chang, L. et al. Dexamethasone prevents TACE-induced adverse events: A meta-analysis. Med. (Baltim). 99, e23191. https:\/\/doi.org\/10.1097\/MD.0000000000023191 (2020).","journal-title":"Med. (Baltim)."},{"key":"1632_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/hep.29403","volume":"67","author":"S Ogasawara","year":"2018","unstructured":"Ogasawara, S. et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology 67, 575\u2013585. https:\/\/doi.org\/10.1002\/hep.29403 (2018).","journal-title":"Hepatology"},{"key":"1632_CR21","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s00520-019-05178-1","volume":"28","author":"T Sakamoto","year":"2020","unstructured":"Sakamoto, T. et al. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Support Care Cancer. 28, 3251\u20133257. https:\/\/doi.org\/10.1007\/s00520-019-05178-1 (2020).","journal-title":"Support Care Cancer"},{"key":"1632_CR22","doi-asserted-by":"publisher","first-page":"e35433","DOI":"10.1097\/MD.0000000000035433","volume":"102","author":"H Lu","year":"2023","unstructured":"Lu, H., Zheng, C., Liang, B. & Xia, X. Efficacy and safety analysis of dexamethasone\u2009+\u2009palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study. Med. (Baltim). 102, e35433. https:\/\/doi.org\/10.1097\/MD.0000000000035433 (2023).","journal-title":"Med. (Baltim)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01632-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01632-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01632-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T09:32:40Z","timestamp":1748079160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01632-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01632-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18095"}}